Answers are grounded in this paper and cite their sources.
The effects of general anesthetics on neurotransmitter uptake by plasma membrane transporters are controversial. We analyzed the effects of representative volatile and IV general anesthetics on recombinant transporters for norepinephrine (human NET), dopamine (rat DAT), or γ-aminobutyric acid (rat GAT-1) stably expressed in a porcine kidney cell line (LLC-PK1). This approach avoids complicating factors associated with neuronal preparations, such as the involvement of multiple transporters and the indirect effects of membrane potential. At clinical concentrations, human NET was inhibited only by halothane (50% inhibitory concentration [IC50] = 0.54 mM), rat DAT was sensitive to both halothane and isoflurane (IC50 = 0.60 and 0.64 mM, respectively), and rat GAT-1 was insensitive to both volatile anesthetics. Human NET was inhibited in a dose-dependent fashion by propofol (IC50 = 41 μM), ketamine (IC50 = 150 μM), and etomidate (IC50 > 200 μM), but not by pentobarbital. Only propofol inhibited NET at a clinically relevant concentration (5 μM). Rat DAT was inhibited in a dose-dependent fashion by propofol (IC50 = 120 μM), etomidate (IC50 = 100 μM), and ketamine (IC50 = 210 μM), but not by pentobarbital. None of these anesthetics was predicted to inhibit DAT at concentrations that produce anesthesia. Propofol inhibited rat GAT-1, but only at the largest concentration tested. General anesthetics have drug- and subtype-selective actions on neurotransmitter transporters. We conclude that effects on catecholamine, but not γ-aminobutyric acid, transporters may contribute to secondary synaptic actions of certain anesthetics but are unlikely to be essential to their anesthetic properties.
No takes yet. Share an insight, caveat, or question.
Shahani et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: